Oregon State University
Corvallis, Oregon, 97331, United States
Location status: Recruiting
Location contact
Emily Ho, PhD
PRINCIPAL_INVESTIGATOR
Sandra Uesugi, RN, BSN, MS
CONTACT
NCT Number: NCT07564674
The goal of this clinical trial is to compare how much glucoraphanin and sulforaphane from 3 different versions of broccoli extract supplements is absorbed into the body and excreted in urine. This study involves generally healthy adults age 18-60 years. The supplements contain glucoraphanin and myrosinase enzyme, both naturally occurring in cruciferous vegetables. Once ingested, glucoraphanin is converted to the bioactive compound sulforaphane, which is thought to have numerous health benefits, including cancer prevention.
Participants will:
* consume 3 different versions of broccoli extract supplements (glucoraphanin will range from 35-70 mg) * complete 3 separate 24 hour study cycles * submit blood and urine samples for 24 hours * follow diet restrictions (no cruciferous vegetables or condiments or phytochemical/herbal supplements for 1 week prior to and during each study cycle)
Interested in participating?
Request Info18 year–60 year
All sexes
Interventional
Not applicable
Corvallis, Oregon, 97331, United States
Location status: Recruiting
Emily Ho, PhD
PRINCIPAL_INVESTIGATOR
Sandra Uesugi, RN, BSN, MS
CONTACT
This study aims to compare the bioavailability of 3 different versions of a broccoli extract supplement in generally healthy adults age 18-60 years who do not smoke or are not pregnant/lactating. The supplements contain glucoraphanin and myrosinase enzyme, both naturally occurring in cruciferous vegetables. Once ingested, glucoraphanin is converted to the bioactive compound sulforaphane, which is thought to have numerous health benefits, including cancer prevention. The amount of glucoraphanin that subjects will take will range from 35-70 mg. Glucoraphanin, sulforaphane, and sulforaphane metabolites will be measured in plasma and urine for 24 hours (plasma: 0, 0.5, 1, 2, 4, 8, and 24 hours after supplement consumption; urine: 0-2, 2-4, 4-8, and 8-24 hour after supplement consumption).
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Participants will swallow by mouth 1 tablet Avamacol Extra Strength with coating (35 mg glucoraphanin per tablet)
Participants will chew and swallow by mouth 2 wafers Avmacol chewable wafers (30 mg glucoraphanin per wafer)
Participants will swallow by mouth 2 tablets Avamacol Extra Strength with coating (35 mg glucoraphanin per tablet)
Time frame: 0, 2, 4, 8, and 24 hours
Change from baseline levels of sulforaphane in urine
Time frame: 0, 2, 4, 8, and 24 hours
Change from baseline levels of sulforaphane in urine
Time frame: 0, 1, 2, 4, 8, and 24 hours
Change from baseline levels of plasma glucoraphanin
Time frame: 0, 1, 2, 4, 8, and 24 hours
Change from baseline levels of plasma sulforaphane
Time frame: 0, 1, 2, 4, 8, and 24 hours
Change from baseline levels of plasma sulforaphane metabolites
Contact information is provided by the study sponsor or research team.
Emily Ho, PhD
CONTACT
Sandra Uesugi, RN, BSN, MS
CONTACT
Oregon State University
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06099288
Diet, Healthy, Glucose Metabolism Disorders
Providence, Rhode Island, United States
View Trial DetailsNCT06814509
Body Weight, Body Weight Changes
Corning, Arkansas, United States
View Trial DetailsNCT06565104
Behavior, Blood Pressure
New York, United States
View Trial DetailsNCT06489262
Activity, Motor, Behavior
Miami, Florida, United States
View Trial Details